You are here

Development of a broad spectrum antimicrobial to combat chronic lung infection

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL162238-01A1
Agency Tracking Number: R43HL162238
Amount: $300,590.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA21-259
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-08-10
Award End Date (Contract End Date): 2023-07-31
Small Business Information
Lebanon, NH 03766-1441
United States
DUNS: 828763263
HUBZone Owned: Yes
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (858) 401-3906
Business Contact
Phone: (617) 320-8521
Research Institution

Project Summary
Bacterial resistance has reached alarming levels in the US and other parts of the world in the past decade. The
increase in bacterial infection with antimicrobial resistant (AMR) pathogens are resulting in increasing healthcare
costs and a decline in positive clinical outcomes. According to the Center for Disease Control’s Antibiotic
Resistance Threats in the United States 2019 report (2019 AR Threats Report), more than 2.8 million antibiotic-
resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. New therapies for
controlling these AMR pathogen-induced infections are urgently needed because: (a) the mortality rate among
infected individuals requiring hospitalization remains very high; and (b) overuse of antibiotics has resulted in
continuing emergence of additional multi-drug resistant (MDR) strains.
There is a dire need to develop novel antimicrobial compounds that have a broad spectrum of activity against
AMR bacteria that are both well tolerated and have a low propensity to select for resistant strains of bacteria.
Our long-term goal is to develop an effective, safe therapeutic to MDR pathogens determined to be critical and
high priority by the CDC and the World Health Organization (WHO).
We seek to develop our lead antimicrobial peptide, CM-YPD1, with broad-spectrum activity against clinical
isolates of ESKAPE pathogens to treat the growing number of patients with MDR infections. This proposal
focuses on development of CM-YPD1 for treatment of chronic lung infection in cystic fibrosis patients. Our
multidisciplinary team brings together a unique combination of academic and commercial expertise that will
permit the development of a drug that can be used to treat the growing number of patients with life-threatening
MDR bacterial infections.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government